Login für Fachkreise

Grauer Banner mit roter Aufschrift 'Update'

Glenmark Newsroom - Aktuelle Pressemitteilungen

Pressemitteilungen

2023

10.02.2023: Glenmark Pharma reports revenue growth of 9.2% and PAT growth of 21.3% YoY for Q3 FY 2022-23

2022

17.11.2022: Vier für die Familie – natürliche OTC-Produkte zur Kindergesundheit neu bei Glenmark
11.11.2022: Glenmark Pharma reports revenue growth of 7.2% YoY and EBITDA margin of 18.4% for Q2 FY 2022‐23
10.08.2022: Glenmark Pharma reports Revenue of INR 27,773 Mn and PAT of INR 2,111 for Q1 FY 2022-23
28.06.2022: Glenmark Pharmaceuticals Inc., USA continues to expand its Over-The-Counter (OTC) Portfolio with the acquisition of approved ANDAs from Wockhardt Limited
27.05.2022: Glenmark Pharma reports revenue growth of 5.6% YoY Q4; 12.4% for the full year FY 2021-22
11.02.2022: Glenmark Pharma reports revenue growth of 13.9% and EBITDA growth of 30.8% YoY for Q3 FY 2021-22

2021

2020

2019

2018

2017

2016

2015

2014

04.11.2014: Enrollment Begins of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis

Pressekontakt

Glenmark Arzneimittel GmbH
Industriestraße 31
82194 Gröbenzell

Telefon:
+49 (0) 800 - GLENMARK
+49 (0) 800 - 45366275 (kostenfrei)

Fax:
+49 (0) 8142 - 4439229

E-Mail:
service.de@glenmarkpharma.com

‹ › ×